Trade BCAX stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Bicara Therapeutics Inc. (BCAX) is trading at US$22.64, up 0.22% today as of Sep 18, 16:00 EDT. The company has a market capitalisation of US$1.58B. Over the past 52 weeks, BCAX has traded between US$10.30 and US$30.99. On Syfe you can trade BCAX with $0 commission and add it to your watchlist.
| Previous close | US$22.59 |
|---|---|
| Market cap | US$1.58B |
| 52-week range | US$10.30 – US$30.99 |
| Volume | 929.49K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Bicara Therapeutics Inc.
Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company’s bi-functional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Its products include BCA101, a first-in-class EGFR/TGF-ß-trap bifunctional antibody in clinical development for multiple tumor types. The company was founded on December 12, 2018 and is headquartered in Boston, MA.
Year: 2024
BMO Capital Initiates Bicara Therapeutics at Outperform
Aug 19, 10:10 AM · MT Newswires
Bicara Therapeutics Insider Sold Shares Worth $524,533, According to a Recent SEC Filing
Aug 12, 8:31 PM · MT Newswires
Bicara Therapeutics Insider Sold Shares Worth $279,750, According to a Recent SEC Filing
Aug 12, 8:31 PM · MT Newswires
Bicara Therapeutics Insider Sold Shares Worth $349,591, According to a Recent SEC Filing
Aug 12, 8:30 PM · MT Newswires
Bicara Therapeutics' Cancer Study On Track for 2026 Enrollment, Wedbush Says
Aug 11, 5:28 PM · MT Newswires
Bicara Therapeutics Inc. (BCAX) stock is trading at US$22.64, +0.22% from the previous close of US$22.59.
The market cap for Bicara Therapeutics Inc. (BCAX) stock is approximately US$1.58B.
The 52-week high for Bicara Therapeutics Inc. (BCAX) stock is US$30.99.
The 52-week low for Bicara Therapeutics Inc. (BCAX) stock is US$10.30.
Bicara Therapeutics Inc. (BCAX) does not currently pay a dividend.
Stay on top of BCAX
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
